Immunothérapie : Libre accès
Libre accès

Abstrait

AEBP1 Predicts Clinical Prognosis and is Associated with Immunocyte Infiltration in Gastric Cancer

Junsheng Deng*, Ting Zhan*, Xiaoli Chen, Yiyuan Wan, Mengge Chen, Jiaxi Liu，Xiaodong Huang, Xia Tian

Adipocyte enhancer-binding protein 1 (AEBP1) is differentially expressed in various tumors. However, the relationship between AEBP1 and immune cell infiltration in Gastric Cancer (GC) remains unclear. Epigenetic regulation and transcriptional expression of AEBP1 in various clinicopathological parameters were detected using UALCAN database. Associations between infiltrating immune cells and their corresponding gene marker panels and AEBP1 expression were examined using the TIMER database. Kaplan-meier survival curve was used to evaluate the relationship between AEBP1 expression and overall survival and progression-free survival. AEBP1 expression in GC tissues was higher than that in normal tissues (P<0.05). The high expression of AEBP1 and the high methylation level of AEBP1 were associated with the high incidence and TNM stage of malignant tumor. In addition, the expression of AEBP1 in GC was associated with immune-related genes such as CD3E, CD3D, and CD2, and immune-infiltrating cells such as CD8⁺ T-cells and CD4⁺ T-cells, neutrophils, and macrophages. The methylation sites CG00009293, CG08495088, CG12955216, CG10480062, CG06852744, and CG12978582 were related to the low expression of AEBP1. AEBP1 may be a potential oncogenic gene and a new therapeutic target and predictive biomarker for gastric cancer. In immune cell infiltration, AEBP1 may play an important role.